TD Cowen lowered the firm’s price target on HCA Healthcare (HCA) to $361 from $377 and keeps a Buy rating on the shares. The firm updated its modle following Q1 results while noting FY25 guidance was maintained given uncertainty around tariffs and broader policy environment.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare: Balanced Risk/Reward Profile Justifies Hold Rating Amid Strong Performance and High Valuation
- HCA Healthcare: Strong Financial Performance and Strategic Initiatives Drive Buy Rating
- HCA Healthcare Reports Strong Q1 2025 Results
- HCA Healthcare Reports Strong Q1 Earnings Growth
- China weighs U.S. tariff exemptions, Alphabet reports Q1 beat: Morning Buzz